NASH With Fibrosis

Metabolic Diseases
3
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Akero Therapeutics
Akero TherapeuticsCA - South SF
1 program
1
EfruxiferminPhase 31 trial
Active Trials
NCT06215716RecruitingEst. Nov 2032
Hepion Pharmaceuticals
2 programs
1
1
rencofilstat, 75 mgPhase 21 trial
[14C]-rencofilstat 225mgPhase 11 trial
Active Trials
NCT05737433Completed6Est. Aug 2023
NCT05461105Completed60Est. Jul 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Non-alcoholic Steatohepatitis Registry Platform StudyN/A1 trial
Active Trials
NCT06123858Terminated1,122Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Akero TherapeuticsEfruxifermin
Hepion Pharmaceuticalsrencofilstat, 75 mg
Hepion Pharmaceuticals[14C]-rencofilstat 225mg
AstraZenecaNon-alcoholic Steatohepatitis Registry Platform Study

Clinical Trials (4)

Total enrollment: 1,188 patients across 4 trials

NCT06215716Akero TherapeuticsEfruxifermin

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Start: Dec 2023Est. completion: Nov 2032
Phase 3Recruiting
NCT05461105Hepion Pharmaceuticalsrencofilstat, 75 mg

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3

Start: Mar 2022Est. completion: Jul 202360 patients
Phase 2Completed
NCT05737433Hepion Pharmaceuticals[14C]-rencofilstat 225mg

Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

Start: Mar 2023Est. completion: Aug 20236 patients
Phase 1Completed
NCT06123858AstraZenecaNon-alcoholic Steatohepatitis Registry Platform Study

Non-alcoholic Steatohepatitis Registry Platform Study

Start: Nov 2023Est. completion: Oct 20251,122 patients
N/ATerminated

Related Jobs in Metabolic Diseases

Manager, Patient Safety and Pharmacovigilance Operations

Kailera Therapeutics
Waltham, Massachusetts
8h ago

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
Yesterday

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Application & Integration Architect

Roche
Indianapolis
5d ago
$106K - $196K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,188 patients
3 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)